Discoveries during the prior period of support demonstrated that PKCe is a key enzyme that down-regulates GABAA receptor function through three mechanisms: (1) modulation of allosteric sensitivity via phosphorylation of receptor subunits;(2) down-regulation of cell surface abundance, possibly through phosphorylation of the N-ethylmaleimide-sensitive factor (NSF), and (3) down-regulation of GABAA receptor function. In this continuation, we will extend this work by examining PKCe phosphorylation of 32 and y2S GABAA receptor subunits, the regulation of NSF by PKCe, the role of cofilin-1 and cyclophilin A as possible PKCe substrates that regulate GABAA receptor sensitivity to allosteric drugs, and the role of increased a2 subunit abundance in the striatum in mediating PKCe null phenotypes. Studies will use transfected cell lines expressing specific receptor subunit combinations and an analog-sensitive mutant of PKCs. Other studies will use primary neurons cultured from PKCe null and wild type mice. Phosphorylation sites will be identified by mass spectrometry and phosphorylation site alanine mutants will be constructed to determine if these mutations prevent phosphorylation by PKCe. GABAA receptor currents in intact cells will be examined by whole cell patch clamp. a2 subunits will be overexpressed in the striatum to see if overexpression reduces alcohol consumption in wild type mice. An RNAi vector will be developed to knock down ot2in the striatum to determine if decreasing expressing of a2 subunits increases alcohol consumption in PKCe null mice. These studies will provide novel molecular information about how PKCe regulates the sensitivity of GABAA receptors to ethanol and will provide new information about how PKCe regulates GABAA receptor cell surface s1 ability and function. PERFORMANCE SITE(S) (organization, city, state) Ernest Gallo Clinic and Research Center Emeryville, CA PHS 398 (Rev. 09/04) Page 2 Form Page 2 Principal Investigator/Program Director (Last, First, Middle): Messing, Robert O. KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shown below. Start with Principal Investigator. List all other key personnel in alphabetical order, last name first. Name eRA Commons User Name Organization Role on Project Messing, Robert O. ROBERM Ernest Gallo Clinic and Principal Investigator Research Center (EGCRQ Chou, Wen-Hai N/A EGCRC Assoc. Investigator Qi, Zhan-Heng N/A EGCRC Postdoctoral Fellow OTHER SIGNIFICANT CONTRIBUTORS Name Organization Role on Project Shokat, Kevan M. UCSF Collaborator Human Embryonic Stem Cells ^ No (H Yes If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list http://stemcells.nih.qov/reqistrv/index.asp. Usecontinuation pages as needed. If a specific line cannot be referencedat this time, include a statement that one from the Registry will be used. Cell Line Disclosure Permission Statement. Applicable toSBIR/STTR Only. See SBIR/STTR instructions. Cl Yes d No PHS 398 (Rev. 09/04) Page 3 Form Page 2-continued Number the following pages consecutively throughout the application. Do not use suffixes such as 4a, 4b. Principal Investigator/Program Director (Last, First, Middle): Messing, Robert O. The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description,

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AA013588-09
Application #
7813947
Study Section
Special Emphasis Panel (NSS)
Program Officer
Liu, Qi-Ying
Project Start
2002-05-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
9
Fiscal Year
2010
Total Cost
$412,830
Indirect Cost
Name
Ernest Gallo Clinic and Research Center
Department
Type
DUNS #
173995366
City
Emeryville
State
CA
Country
United States
Zip Code
94608
Pomrenze, Matthew B; Fetterly, Tracy L; Winder, Danny G et al. (2017) The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? Alcohol Clin Exp Res 41:1986-1999
Maiya, Rajani; McMahon, Thomas; Wang, Dan et al. (2016) Selective chemical genetic inhibition of protein kinase C epsilon reduces ethanol consumption in mice. Neuropharmacology 107:40-48
Blasio, Angelo; Messing, Robert O (2016) Binge Drinking With Protein Kinase C Epsilon: A Role for Mammalian Target of Rapamycin Complex 2? Biol Psychiatry 79:425-6
Lee, A M; Wu, D-F; Dadgar, J et al. (2015) PKC? phosphorylates ?4?2 nicotinic ACh receptors and promotes recovery from desensitization. Br J Pharmacol 172:4430-41
Trudell, James R; Messing, Robert O; Mayfield, Jody et al. (2014) Alcohol dependence: molecular and behavioral evidence. Trends Pharmacol Sci 35:317-23
Ron, Dorit; Messing, Robert O (2013) Signaling pathways mediating alcohol effects. Curr Top Behav Neurosci 13:87-126
Lee, Anna M; Messing, Robert O (2011) Protein kinase C epsilon modulates nicotine consumption and dopamine reward signals in the nucleus accumbens. Proc Natl Acad Sci U S A 108:16080-5
Chou, Wen-Hai; Wang, Dan; McMahon, Thomas et al. (2010) GABAA receptor trafficking is regulated by protein kinase C(epsilon) and the N-ethylmaleimide-sensitive factor. J Neurosci 30:13955-65
Newton, Philip M; Messing, Robert O (2010) The substrates and binding partners of protein kinase Cepsilon. Biochem J 427:189-96
Wallace, Melisa J; Newton, Philip M; McMahon, Thomas et al. (2009) PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2. Neuropsychopharmacology 34:1733-42

Showing the most recent 10 out of 35 publications